Mobile website
Archive > Volume 30 Issue 4 > 2023,30(4):331-337. DOI:10.3872/j.issn.1007-385X.2023.04.008 Prev Next
Clinical Research
Efficacy evaluation of camrelizumab combined with apatinib in the treatment of primary hepatocellular carcinoma
- Article
- Figures
- Metrics
- Preview PDF
- Reference
- Related
- Cited by
- Materials
Abstract:
Objective: To reevaluate the efficacy and safety of camrelizumab combined with apatinib in the treatment of primary hepatic carcinoma (PHC). Methods: The clinical data of PHC patients diagnosed in the First Affiliated Hospital of Anhui Medical University from January 2019 to May 2021 were retrospectively collected. All patients received camrelizumab 200 mg q3w combined with apatinib 250 mg qd for 21 days. Chi-square test was used to compare the baseline characteristics. Kaplan-Meier method was used to calculate the survival curve, from which the median total survival (OS) was estimated, and then Log-Rank test was used for comparison; Single factor Cox regression analysis was used to predict the factors affecting OS. Results: A total of 43 patients with PHC were included in this study. The objective response rate (ORR) of first-line treatment patients was 23.3% (7/30), and the ORR of second-line and above treatment patients was 15.4% (2/13). The disease control rate (DCR) of the two groups were 83.3% (25/30) and 61.5%(8/13), respectively. The median progression-free survival (PFS) was 5.0 months (95% CI 3.2, 6.8) and 4.0 months (95% CI 1.7, 6.3) (P=0.514), respectively. The median total survival (OS) was 13.0 months (95% CI 11.2, 14.8) and 9.0 months (95% CI 2.8, 15.2) (P=0.179). Among 43 patients, 33 (76.7%) had treatment-related AEs of grade 3 or above. The most common AEs were decreased platelet count (14.0%), hypertension (9.3%) and proteinuria (9.3%). Cox univariate analysis showed that Child-Pugh grade was an independent risk factor affecting the prognosis of PHC patients (HR=0.324, 95% CI [0.146, 0.716], P<0.05). Conclusion: Camrelizumab plus apatinib significantly improved OS, ORR, and DCR in PHC patients , AEs were tolerable and manageable.
Keywords:
Project Supported:
Clc Number:
